Biolight (BOLT) AI Stock Analysis

0 Followers

Biolight

(TASE:BOLT)

Select Model

Rating:37Underperform

Price Target:ILA 277.00▼(-2.29% Downside)

Action:downgraded

Date:08/21/26

The stock scores at the lowest possible level of 37, reflecting severe fundamental and technical distress. The company is pre-revenue with deep losses and significant cash burn, while the stock price is in a strong downtrend across all timeframes. The only positive, a solid balance sheet, is insufficient to offset the overwhelming negative signals from the income statement, cash flows, and market momentum.

Positive Factors

Low leverageVery low leverage reduces refinancing and solvency pressure, preserving more flexibility than a highly indebted balance sheet. This can help Biolight direct available resources toward product development and commercialization while limiting interest-related demands on future cash flow.

Negative Factors

Minimal and volatile revenueRevenue has not demonstrated a dependable growth trajectory and reached zero in the latest reported year. Such limited and volatile sales make it difficult to absorb the existing cost base, validate commercial traction, or establish a reliable foundation for sustainable earnings.

Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)

Market Cap: ILS 25.65M
Dividend Yield: ―
Average Volume (3M): 10.27K
Price to Earnings (P/E): -2.1
Beta (1Y): 0.63
Revenue Growth: -100.00%
EPS Growth: -29.02%
Country: Israel
Employees: 4
Sector: General
Sector Strength: 55
Industry: Medical - Specialties

Biolight Business Overview & Revenue Model

Company Description

BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include...

Biolight Financial Statement Overview

Summary

Financial performance is critically weak. The income statement reflects zero revenue and persistent, deep operating losses. Cash flow is consistently negative with significant cash burn. The only mitigating factor is a relatively strong balance sheet with low debt and a recent equity infusion, preventing a score at the absolute floor.

Income Statement

15Very Negative

Balance Sheet

45Neutral

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	219.00K	118.00K	63.00K	3,000
Gross Profit	-270.00K	-544.00K	219.00K	118.00K	63.00K	3,000
EBITDA	-14.65M	-14.66M	-7.75M	-10.08M	-8.03M	-1.36M
Net Income	-11.74M	-11.73M	-7.14M	-26.02M	-7.85M	382.00K
Balance Sheet
Total Assets	35.06M	42.41M	34.12M	33.45M	57.01M	64.17M
Cash, Cash Equivalents and Short-Term Investments	16.19M	23.65M	13.47M	8.64M	17.63M	33.71M
Total Debt	1.06M	772.00K	599.00K	91.00K	527.00K	443.00K
Total Liabilities	3.86M	2.24M	3.38M	3.15M	3.32M	2.75M
Stockholders Equity	28.09M	34.40M	26.88M	29.78M	53.17M	60.70M
Cash Flow
Free Cash Flow	-11.92M	-10.86M	-11.02M	-10.99M	-9.64M	-10.65M
Operating Cash Flow	-11.92M	-10.85M	-10.99M	-9.58M	-9.54M	-10.03M
Investing Cash Flow	-11.96M	-16.17M	7.55M	-1.95M	-10.55M	13.48M
Financing Cash Flow	21.36M	21.37M	7.98M	3.25M	-485.00K	915.00K

Biolight Technical Analysis

Technical Analysis SentimentNegative

Last Price283.50

Price Trends

50DMA288.81Negative

100DMA326.75Negative

200DMA320.45Negative

Market Momentum

MACD-0.02Positive

RSI45.63Neutral

STOCH54.14Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 283.50 is below the 20-day moving average (MA) of 286.67, below the 50-day MA of 288.81, and below the 200-day MA of 320.45, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.63 is Neutral, neither overbought nor oversold. The STOCH value of 54.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.

Biolight Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IL:BOLT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IL:PPBT	46Neutral	ILS 32.42M	-0.01	―	―	―	-125.74%
IL:BLRX	41Neutral	ILS 29.87M	-1.02	―	―	-93.07%	62.25%
IL:CANF	38Underperform	ILS 15.56M	-0.23	―	―	―	―
IL:BOLT	37Underperform	ILS 25.74M	-2.12	―	―	-100.00%	-29.02%

* General Sector Average

Performance Comparison

IL:BOLT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IL:BOLT	BioLight Life Sciences Ltd.	283.50	-119.60	-29.67%
IL:BONS	Bonus Biogroup	16.10	-5.90	-26.82%
IL:CBI	Clal Biotechnology Industries Ltd	24.20	-7.00	-22.44%
IL:BLRX	BioLineRX Ltd.	1.00	-0.90	-47.37%
IL:CANF	Can-Fite BioPharma Ltd.	271.10	270.10	27010.00%
IL:PPBT	Purple Biotech Ltd.	1.00	-0.30	-23.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026

Biolight AI Stock Analysis